Japanese National Health Insurance System approves Orladeyo addition to drug price list
The Japanese National Health Insurance System (NHI) has approved the addition of oral, once-daily Orladeyo (berotralstat) from BioCryst Pharmaceuticals, Inc. to the NHI drug price list on 21 April 2021. Oral, once-daily Orladeyo was approved in Japan in January 2021 for prophylactic treatment of HAE in adults and pediatric patients 12 years and older. Orladeyo [...]